USPTO has granted patent US12594323B2 to ImmunityBio, Inc. for multi-chain chimeric polypeptides and their use in reducing neuroinflammation. The patent covers compositions and methods with 26 claims, classified under A61K 38/1793, A61K 38/20, A61P 25/28, and related categories. This grant provides ImmunityBio with exclusive rights to the patented technology, potentially affecting competitors developing similar neuroinflammatory treatments.

Affected parties including pharmaceutical companies, biotechnology firms, and research institutions working on neuroinflammatory disease therapeutics should review this patent to assess potential licensing needs or design-around considerations. The patent's broad claims on multi-chain polypeptide compositions may create IP clearance obligations for parties in the neuroinflammation treatment space.